Antivirals

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

• Study Reliability and Reporting Limitations
• Disclaimers
• Data Interpretation & Reporting Level
• Quantitative Techniques & Analytics
• Product Definitions and Scope of Study
• HIV Antivirals
• NRTIs
• NNRTIs
• Protease Inhibitor (PI)
• Other HIV Antivirals
• Hepatitis B & C Antivirals
• Hepatitis B Antivirals
• Hepatitis C Antivirals
• Herpes Simplex Virus (HSV) Antivirals
• Influenza Antivirals
• Respiratory Syncytial Virus (RSV) Antivirals
• Human Papilloma Virus (HPV) Antivirals
• Other Antivirals

II. EXECUTIVE SUMMARY

1. Market Overview

• Viruses, a Difficult - to - Treat Class of Parasites
• United States - The Largest Market for Antivirals Globally
• Five Major Antivirals Dominate the Overall Antivirals Arena
• Table 1: Worldwide Infectious Disease Drugs Market by Class: 2005 Percentage Share Breakdown by Typefor Antivirals, Quinolones, Macrolides, Penicillins, Cephalosporins, Antifungals, Tetracyclines, Erythromycins and Other Therapies in US$ million (includes corresponding Graph/Chart)
• Anti-HIV Drugs - The Largest Antivirals Category Worldwide
• US - Largest Region, and Japan - Fastest Growing Region for HIV Antivirals
• Table 2: World HIV Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart)
• Table 3: World HIV Antivirals Market by Geographic Region - Percentage Share Breakdown for US, Japan, Europe, and Rest of World (excluding Japan) for the Year 2006 (includes corresponding Graph/Chart)
• Leading Players and Drugs
• Top 10 HIV Antiviral Drug Candidates by Global Sales
• New Drugs in Pipeline to Boost up the HIV
• Antivirals Sales
• Hepatitis Antivirals - A Significant Market
• US Dominates the Hepatitis B & C Antivirals Market
• Table 4: World Hepatitis B & C Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart)
• Hepatitis C Antivirals - The Fastest Growing Antivirals Segment
• U S Dominates the Hepatitis C Antivirals Market
• Table 5: World Hepatitis C Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart)
• The US Dominates the Hepatitis B Antivirals Market
• Table 6: World Hepatitis B Antivirals Market by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) with Annual Sales Figures in US$ Million for Years 2006 & 2010 (includes corresponding Graph/Chart)
• Growing Patient Population to Drive up Hepatitis B Drugs Market
• Influenza Anti-Virals
• Rising Threat of Avian Flu to Drive up the Market for Antivirals
• Herpes and Respiratory Antivirals
• HSV/VZV Drugs Dominate the Herpes and Respiratory Antivirals Market
• Launch of New Drugs to Drive up the Market for Respiratory Antivirals

2. Competitive Landscape

• Players Active in the HIV Antivirals Market
• Table 7: Leading Drug Brands for HIV Infection in the World: 2005 Sales (in $ million) for Combivir, Kaletra, Viread, Reyataz, Sustiva, Trizivir, Epivir, and Epzicom/Kivexa (includes corresponding Graph/Chart)
• Major HIV Antivirals Brands Available in the Market
• Nucleoside Reverse Transcriptase Inhibitors (NRTIs) Brands
• Epivir (Lamivudine)
• Retrovir (Zidovudine)
• Combivir (Epivir+Retrovir)
• Videx (Didanosine)
• Zerit (Stavudine)
• Hivid (Zalcitabine)
• Protease Inhibitors (PIs)
• Norvir (Ritonavir)
• Kaletra (Lopinavir+Ritonavir)
• Agenerase (Amprenavir)
• (VX-175) Fosamprenavir
• VX-385
• Fusion Inhibitors
• Fuzeon (Enfuvirtide)
• Players Active in the Hepatitis B Virus (HBV) Drugs Market
• Hepsera Leads the Oral Hepatitis B Antivirals Market
• Table 8: Leading Drug Brands for Oral Hepatitis B Antivirals: 2006 Percentage Share Breakdown for Hepsera, Epivir HBV and Baraclude (includes corresponding Graph/Chart)
• Table 9: Leading Antivirals Brands for Hepatitis B Infection in the World: 2005 Sales (in $million) for *Engerix-B, Havrix, and Twinrix; **Infanrix and Pediarix, and Epivir (includes corresponding Graph/Chart)
• Players in the Hepatitis C Virus (HCV) Drugs Market
• Table 10: Leading Drug Brands for Oral Hepatitis B Antivirals in the World: 2005 Sales (in $million) for Pegasys and PEG-Intron
• Table 11: Leading Players in the Pegylated Interferons Market in the World: 2006 Percentage Share Breakdown by Player for Hoffmann-La Roche, Schering-Plough and Others (includes corresponding Graph/Chart)
• Table 12: Leading Therapies for Hepatitis C Infection in the World: 2006, 2010E and 2015E Percentage Share Breakdown for Ribavirin, Interferons, Protease Inhibitors, and Nucleoside Analogs (includes corresponding Graph/Chart)
• Players in the Herpes and Respiratory Antiviral Market
• Table 13: Leading Brands of the Respiratory Antivirals Market in the World: 2005 Sales (in $million) for Tamiflu; Synagis; Infanrix and Pediarix (includes corresponding Graph/Chart)
• Players in the Herpes Simplex Virus (HSV) Therapies Market
• Table 14: Leading Drug Brands for Oral Herpes Antivirals in the World: 2004 Sales (in $million) for Valtrex and Zovirax
• Major HSV Infection Drugs Available
• Zovirax (Aciclovir)
• Famvir (Famciclovir)
• Foscavir (Foscarnet)
• Valtrex (Valaciclovir)
• Vectavir/Denavir (Penciclovir)
• Abreva (Docosanol)
• Players in the Influenza Market
• Major Influenza Drugs Available
• Symmetrel® (Amantadine)
• Flumadine (Rimantadine)
• Tamiflu (Oseltamivir)
• Relenza (Zanamivir)
• Players in the Antivirals (Non-HIV) Market
• Table 15: Global Leading Players in the Antivirals (Non-HIV) Market: 2005 Percentage Share Breakdown for GlaxoSmithKline (GSK), Novartis, Roche, Schering-Plough and Others (includes corresponding Graph/Chart)
• Players Active in the Antiviral Vaccines Market
• Table 16: Leading Antiviral Vaccines Sales (in US$ million) in US/Europe in 2003 (includes corresponding Graph/Chart)
• Table 17: Leading Players in the US & **5EU Vaccines Markets: 2005 Percentage Share Breakdown by Player for GlaxoSmithKline (GSK), Sanofi-Aventis, Merck, *Novartis (Chiron) and Others (includes corresponding Graph/Chart)
• Product Pipeline Development of Hepatitis C Drugs as of 2006

3. Market Trends & Issues

• Increased Investment in R&D to Fuel Growth
• Preventative Antivirals Gains Significance
• New Drug Types Fuels Up the HIV Drugs Sector
• Development of Direct Targeted Antiviral Therapies
• Advent of Novel Anti-Viral Peptides
• siRNA Shows Potential to Function as Antiviral Agent
• Reduction of HIV/AIDS Therapy Costs Boost Market Growth
• Combination Drug Therapy Gains Popularity in the Anti-HIV Drugs Market
• Empowering Women to Fight Against Spread of HIV Infection
• Prices to Go Up for Novel Antivirals
• Competition Scales up for Nucleoside/Nucleotide Analogs Class of Hepatitis Antivirals
• Emergence of Oligonucleotide (ODN) Agents in HIV Drugs Market
• PMBs to Invade the Antivirals Market
• Acute Shortage Witnessed for the Influenza Vaccine for the 2004-05 Season
• New Therapies for Treatment Naive Hepatitis Patients
• Adult and Travel Vaccines to Drive Up the Market for Antiviral Vaccines
• Researches to Develop Antivirals for Other Miscellaneous Viral Diseases on Full Swing
• Growth to Slow Down Considerably for Herpes Antiviral Market
• STDs, a Major Concern the World Over
• Microbiocides, a New Way to Fight STD and HIV Infections
• Spread of HIV Infection Poses a Global Health Risk

4. An Overview of Major Viral Epidemics & Pandemics in the World

• HIV/AIDS Pandemics
• HIV/AIDS Cases for 2005 in the World
• Highlights of AIDS Epidemic
• Table 18: Global HIV/AIDS Statistics in 2005
• (in Million) (includes corresponding Graph/Chart)
• Table 19: Regional Statistics for HIV/AIDS Cases in 2005 (in Million) (includes corresponding Graph/Chart)
• Table 20: Deaths Due to AIDS Worldwide: Breakdown by Region- 2004 (in Million) (includes corresponding Graph/Chart)
• Table 21: HIV/AIDS Cases in Adults and Children Worldwide: Breakdown by Region-End 2004
• Table 22: Countries With the Highest Number of People Living with HIV: 2003 (includes corresponding Graph/Chart)
• Various Organizations Actively Supports HIV/AIDS Awareness and Preventive Measures Programs
• Table 23: Regional Distribution of Requirement of Funding for Prevention of AIDS: Percentage Share Breakdown for Africa, East Asia-Pacific, South & South East Asia, Eastern Europe, Latin America & Caribbean Region, and North Africa & Middle East in 2006 (includes corresponding Graph/Chart)
• Table 24: Regional Distribution of Requirement of Funding for Treatment and Care of AIDS: Percentage Share Breakdown for Africa, Latin America & Caribbean Region, East Asia-Pacific, Eastern Europe, South & South East Asia, and North Africa & Middle East in 2006 (includes corresponding Graph/Chart)
• Hepatitis B Virus (HBV) Infection Epidemic
• Hepatitis C Virus (HCV) Infection Epidemic
• Table 25: Diagnosis of Hepatitis C Infection in the World: 2005 Percentage Share Breakdown by Transmission Category for Injecting Drug Use (IDU), Sexual Contact, Contaminated Blood Transfusion and Others (includes corresponding Graph/Chart)
• Influenza - Major Outbreaks

5. Anti-Virals : Product Overview

• What are Viruses?
• RNA & DNA Viruses
• Emergence of Antivirals
• Functions of Antivirals
• Design Strategies for Antivirals Drugs
• Vaccines, the Antivirals for Initial Stage of Viral Infection
• Antivirals for Other Stages of Viral Life Cycle
• Entry Blockers
• Viral Component Replication Blockers
• Viral Component Assimilation Blockers
• Antisense Molecules
• Synthetic Ribozymes
• Protease Inhibitors
• Blockers for Release of Completed Viruses from the Host Cell
• Other Types of Antivirals
• Interferons
• Synthetic Monoclonal Antibodies
• Factors Governing Developments in Antiviral Technology

6. Major Viral Infections and Treatment Worldwide

• Human Immunodeficiency Virus (HIV)
• Transmission of HIV Infection
• Infection Process - Targets for HIV Therapy
• Symptoms of the Infection
• Most Vulnerable Demographics for HIV Infection
• Preventive Methods for Controlling HIV Infection
• Methods for the Measurement of Viral Load in Patients
• Methods for Determining Drug Resistance in HIV Positive Patients
• Major HIV/AIDS Testing Methods Available
• Diagnostic Tests
• I. Antibody Tests
• A. HIV-1 Screening Tests
• a. Enzyme-linked Immunosorbent Assays/Enzyme Immunoassays (ELISA/EIA)
• b. Home AccessHIV-1 test system/Dried Blood Spot
• c. Rapid Tests...
• B. HIV-1 Antibody Confirmatory Tests
• a. The Western Blot Test
• b. Indirect Immunofluorescent Antibody Assay (IFA)
• c. Line Immunoassay
• d. Radioimmunoprecipitation Assay (RIPA)
• C. HIV-2 Diagnostic Tests and HIV Group "O
• Major Trends in the HIV/AIDS Testing Market
• Rapid Testing- Displays High Potential
• FDA Approved Rapid HIV Tests in US
• Molecular Diagnostics Register Strong Growth in Blood Screening Markets
• Ultra-Rapid HIV-screening tests- A Strong Fight against HIV-Epidemic
• Emergency Room Testing to Help HIV Diagnosis
• Treatments Available for HIV/AIDS Infections
• Major HIV/AIDS Drug Categories Available
• NRTIs
• NNRTIs
• GW695634
• Protease Inhibitor (PI)
• (VX-175) Fosamprenavir
• VX-385
• Integrase Inhibitors (IIs)
• S-1360
• Entry Blockers
• Fusion Inhibitors
• Fuzeon (Enfuvirtide)
• Antiviral siRNAs
• New Products in Pipeline
• HIV Vaccines
• Hepatitis Infection
• Acute Hepatitis Infection
• Chronic Hepatitis Infection
• Treatment Regimens for Hepatitis Infection
• Interferons
• Standard Interferons
• Pegylated Interferons
• Pegasys
• N & PEG-Intron Redipen
• Pegasys Pack
• N & Pegatron
• Ribavirin
• Types of Hepatitis Infection based on Strains
• Hepatitis A Virus (HAV) Infection
• Hipatitis B Virus
• Hepatitis B Virus (HBV) Infection
• Treatments Available for Chronic HBV Infection
• Vaccines Dominates the Category
• Antiviral Drugs Available
• Hepatitis C Virus (HCV) Infection
• Treatments Available for Chronic Hepatitis C Infection
• Products in Pipeline
• Some Alternative Treatments
• Hepatitis D Virus (HDV) Infection
• Hepatitis E Virus (HEV) Infection
• Herpes Simplex Virus (HSV) Infection
• HSV-1 Infection
• HSV-2 Infection
• Neonatal Herpes Simplex Infection
• Treatments Available for HSV Infection
• Table Containing Major HSV Drugs along with their Patent Expiry Dates
• HSV Antivirals Available in the Market
• Treatments for Opthalmic Viral Infections
• Cytovene (Ganciclovir)
• Vistide (Cidofovir)
• Foscavir (Foscarnet)
• Vaccines Against HSV Infection
• Respiratory Viruses Infections
• Influenza Virus
• Influenza A Virus
• Avian Flu
• Influenza - Brief History
• Transmission of Influenza Infection
• Treatments for Respiratory Viruses
• Influenza Vaccines
• Respiratory Syncytial Virus (RSV) Infection
• Other Respiratory Viruses
• Treatments for RSV and other Respiratory Viral Infections
• Human Papilloma Virus (HPV)
• Treatments Available for HPV Infection
• Other Types of Viral Diseases
• Treatment Options Available for Other Types of Viral Diseases
• Overview of Antiviral Vaccines

7. International Organizations Supporting Preventative and Treatment Programs for Viral Infections

• UNHCR
• UNICEF
• WFP
• UNDP
• UNPF
• UNODC
• ILO
• UNESCO
• WHO
• World Bank
• National AIDS Trust

8. Product Developments and Launches

• Bristol-Myers Unveils Baraclude in India
• Chinese and US Researchers Together Develop Purified Antiviral Compounds
• Celldex to Develop a Fusion Protein CDX 2401
• PDSC Launches a Germicidal Disinfectant, Medic Kleen
• REPLICor to Develop Antiviral Drugs
• Valeant Pharmaceuticals to Develop Viramidine(R)
• Biota Discovers a New Group of Antiviral Drugs against RSV
• Serum Launches Q-Vac, a Combination Vaccine
• Chongqing Jiachen to Produce Hepatitis B Vaccine
• IIL Decides to Roll Out Five Vaccines in Indian Market
• Shanta Biotechnics to Foray into US Markets with AlphaFeto and Shanvac B
• GSK Launches Hepsera for Chronic Hepatitis B
• Viral Therapeutics Takes Over Development Rights to Recombinant Human Protein
• Biota Inc Introduces New AZT Nucleotide Mimic Drug for HIV/AIDS
• SciGen Ltd Introduces Sci-B-Vac Vaccine for Hepatitis B in Hong Kong
• Aurobindo Pharma Ltd Launches Indivex and Stavex Anti-HIV Drugs
• Trimeris and Roche Collaboratively Develops Two Fusion Inhibitors

9. Recent Industry Activity

• Adventrx Takes Over SD Pharmaceuticals
• Nutra Pharma to Acquire ReceptoPharm
• Dynavax Acquires German Rhein Biotech
• Barrier Acquires Rights to Market Denavir from Norvartis
• Chimerix Acquires Leroy Townsend Library of Lead Drug Candidates
• Sareum Collaborates with Idenix to Develop Antivirals
• CSIRO Collaborates with Bath University to Create an Oral Antiviral Agent
• GlaxoSmithKline and Shionogi to Co-Develop HIV Drugs
• Inovio Biomedical Corporation Enters into an Agreement with Tripep AB
• Roche Partners with Trimeris to Develop HIV Fusion Inhibitor Drugs
• Pfizer and Monogram Execute a Non-Exclusive Collaboration
• Novartis Enters into an Agreement with Human Genome Sciences
• Medivir Inks Licensing Deal with Tibotec for HBV and HIV Drugs
• Boehringer to Enhance its Canadian Antiviral Research Center
• GSK Receives Pediatric Extension of Hevrix Vaccine in the US
• GSK Completes Phase II Clinical Trial on Promacta
• Schering-Plough Undertakes Clinical Trials on Some Hepatitis Products
• Gilead Sciences and Merck Conducts Clinical Trials (Phase I / II) on HIV Integrase Inhibitor
• Vertex to Start Phase IIb Trials for VX-950
• Schering-Plough Starts Phase II Trials for SCH 503034
• Panacos Pharmaceuticals Initiates Phase 2b Studies on Bevirimat
• Immune Response Corporation Initiates IR103 Phase II Trial
• Health Enhancement Products Inc to Conduct ProAlgaZyme Clinical Trial
• Novartis Secures FDA Approval for Famvir
• Novelos Therapeutics, Inc Gains FDA Acceptance of INDA for NOV-205
• Gilead Sciences and Bristol-Myers-Squibb Obtains FDA License for Atripla
• Tibotec Obtains FDA Approval for Darunavir
• Amazon Receives Consent for Phase I/II Trials for AMZ0026
• MedImmune Applies for Supplemental License for CAIV-T
• FermaVir Pharmaceuticals Obtains FDA Approval for Further Studies on Antiviral Drug Candidate
• Abbott Obtains FDA Assent for ABBOTT PRISM® and PRISM® Blood Screening
• Abbott Receives Authorization from European Commission to Market Kaletra®
• Schering-Plough Receives Marketing Approval for PEG-INTRON® and REBETOL® Drugs
• Idenix and Novartis Submit Drug Application to European Regulators for Telbivudine
• Merck Obtains FDA Approval for Marketing GARDASIL® Vaccine
• Merck' s GARDASIL Vaccine Gets CHMP' s Positive Opinion
• Boehringer Ingelheim Demonstrates the Clinical Trial Results of Aptivus® Capsules
• GlaxoSmithKline Demonstrates Results for H5N1 Pandemic Flu Vaccine Clinical Trials
• GlaxoSmithKline Minimizes Prices of HIV Drugs in Poor Countries
• Donations Rises for AIDS Orphanage in South Africa
• FDA to Ban the Usage of Human Antiviral Drugs for Influenza Treatment in Poultry
• Third Wave Withdraws Lawsuit against Digene Relating to Patent on HPV Drug
• Roche Files Suit against Ranbaxy to Restrain Launch of Antiviral Generic Drug
• Dainippon Pharmaceutical to Merge with Sumitomo Pharmaceuticals
• Abbott and OraSure Enter into Agreement
• Hemispherx Biopharma Signs a Research Agreement with Defence R&D Canada
• LUPIN and Cornerstone Sign Licensing Agreement to Develop Anti-Infective Product
• Trimeris Inc Enters into Collaborative Agreement with ChemBridge Research Laboratories
• Corixa Corporation Collaborates with Lorantis
• Takeda Enters into HPV Collaborative Agreement with 3M
• MedImmune Inks Collaborative Licensing Agreement with Biota
• Pharmasset Enters into License Agreement with Bukwang Pharm
• Chiron and Enanta Pharmaceuticals Enter into HCV PI Development Agreement
• Gilead Sciences Enters into JTK-303 License Agreement with Japan Tobacco
• Alnylam and Isis Enter into Licensing Deal with Stanford University
• Gen-Probe and F. Hoffmann-La Roche Enter into an Agreement
• SciGen Limited Enters into Hepatitis B Vaccine Distribution Agreement with Berna Biotech AG
• GSK Receives Supply Order for Relenza from Governments of Three Countries
• Bristol-Myers to Establish Production Facility in China
• Koronis Initiates Phase 1b Trial for KP-1461 Antiviral
• Gilead Initiates Phase III Clinical Trials for Tenofovir
• Vaccine Research Center Initiates Phase II Trials onAdenovector
• Aethlon Medical Instigates Clinical Trials of HCV
• Hemispherx Biopharma Initiates Alferon LDO Clinical Trials
• Bristol-Myers and Merck Provide IPM with License to Develop HIV Vaccines
• Hi-Tech' s Acyclovir Oral Suspension Secures FDA Approval
• Bristol-Myers Squibb Gains FDA Approval for the company' s Entecavir
• Corixa' s Fendrix® Vaccine Receives European Approval
• Calypte Biomedical' s HIV-1 Urine EIA Screening Test Receives FDA Approval
• Gilead Sciences' s Truvada® Receives Marketing Authorization
• Abbott Receives FDA Approval to Formulate Kaletra in Tablet Form
• Boehringer Ingelheim Receives EU Approval to Market Aptivus
• Boehringer Ingelheim Secures FDA Approval to Market Aptivus
• SciClone Releases Poster Presentation of Zadaxin® Triple Therapy
• GlaxoSmithKline Discloses Clinical Findings for Brecanavir
• Abbott and Celera Secure CE Mark Certification for PCR Test
• Gilead Sciences Cuts Prices for Truvada and Viread for Developing Nations
• Gilead Sued Roche for not Properly Marketing Tamiflu and Receives Damage Payment
• MGI PHARMA to Purchase Zycos
• Benitec Ltd Acquires Avocel Inc
• ID Biomedical Takes Over Vaccine Business of Shire
• SGX Forms Alliance with Roche to Develop New Antivirals
• Epimmune and Innogenetics Extend Collaboration Agreement
• Nucleonics and Novosom Collaborate to Develop New Antivirals
• Gilead Sciences and Achillion Pharmaceuticals Sign Licensing Agreement
• ZymoGenetics Licenses Drug Development Rights to Novo Nordisk
• Cubist and XTL Sign Development Agreement
• Sunesis and Merck Signs Research Agreement
• CytoGenix Files Pre-IND Brief with the FDA
• ViroPharma Signs Licensing Agreement with Schering-Plough
• Hemispherx Inks Agreement with GMC for Development and Commercialization of HIV Antivirals
• DNA-C and NYVAC Combination AIDS Vaccine To Enter Clinical Trial Stage
• GlaxoSmithKline Plc Reduces Anti-AIDS Treatment Prices in Poor Countries
• Gilead Acquires Triangle Pharmaceuticals
• Micrologix Acquires Antivirals Portfolio of Origenix
• Roche Acquires HPV Patent Portfolio from Pasteur Institute
• Johnson & Johnson Enters into an Agreement to Acquire Tibotec-Virco NV
• USL Signs Licensing Agreement with Novactyl
• Micrologix Biotech and Hybridon Signs Collaborative Licensing Agreement
• Novartis Acquires a Portfolio of Antivirals from SmithKline Beecham
• Biota Inc' s Bird Flu Drug Relenza Receives FDA Approval

10. Focus on Select Key Players

• Abbott Laboratories (USA)
• Boehringer Ingelheim (Germany)
• Bristol-Myers Squibb (USA)
• Gilead Sciences (USA)
• GlaxoSmithKline Plc. (UK)
• Hoffmann-La Roche (Switzerland)
• Merck & Co. (USA)
• Novartis AG (Switzerland)
• Pfizer Inc. (USA)
• Schering-Plough Corp. (USA)

11. Global Market Perspective

• Table 26: World Recent Past, Current & Future Analysis for Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 27: World Recent Past, Current & Future Analysis for Antivirals by Product Segment - HIV Antivirals (RTIs {NRTIs and NNTRIs}, PIs and Other HIV Antivirals), Hepatitis B & C Antivirals (Hepatitis C Antivirals and Hepatitis B Antivirals), HSV Antivirals, Influenza Antivirals, RSV Antivirals, HPV Antivirals, and Other Antivirals Independently Analyzed by Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 28: World 10-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
• Table 29: World 10-Year Perspective for Antivirals by Product Segment - Percentage Breakdown of Dollar Sales for HIV Antivirals (RTIs {NRTIs and NNTRIs}, PIs and Other HIV Antivirals), Hepatitis B & C Antivirals (Hepatitis C Antivirals and Hepatitis B Antivirals), HSV Antivirals, Influenza Antivirals, RSV Antivirals, HPV Antivirals, and Other Antivirals for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
• Table 30: World Recent Past, Current & Future Analysis for HIV Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 31: World 10-Year Perspective for HIV Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
• Table 32: World Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 33: World 10-Year Perspective for Hepatitis B & C Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
• Table 34: World Recent Past, Current & Future Analysis for Hepatitis C Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 35: World 10-Year Perspective for Hepatitis C Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
• Table 36: World Recent Past, Current & Future Analysis for Hepatitis B Antivirals by Geographic Region - US, Japan, Europe and Rest of World (excluding Japan) Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)
• Table 37: World 10-Year Perspective for Hepatitis B Antivirals by Geographic Region - Percentage Breakdown of Dollar Sales for US, Japan, Europe and Rest of World (excluding Japan) Markets for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

• A. Market Analysis
• Infectious Disease Drugs Market in the US
• Table 38: Infectious Disease Drugs Market by Class in the US: 2005 Percentage Share Breakdown by Type for Quinolones, Penicillins, Macrolides, Antifungals, Cephalosporins, Antivirals, Tetracyclines, Erythromycins and Other Therapies in US$ million (includes corresponding Graph/Chart)
• Antivirals Market Perspective in the US
• HIV Antivirals Dominate the Antiviral Therapies Market in the US, followed by the Hepatitis B & C Antivirals Class
• Table 39: Antivirals Market by Type in the US: 2006 Percentage Share Breakdown for HIVAntivirals, Hepatitis B & C Antivirals, and Other Antivirals (includes corresponding Graph/Chart)
• Combivir Dominates the Reverse Transcriptase Inhibitors Market in the US
• Table 40: Reverse Transcriptase Inhibitors Market by Brand Type in the US: 2005 Percentage Share Breakdown for Combivir, Zerit, Epivir, Sustiva, Viramune, Ziagen, Videx, Retrovir and *Others (includes corresponding Graph/Chart)
• Table 41: Leading Players in the HIV Reverse Transcriptase Inhibitors (RTIs) Market in the US: 2005 Percentage Share Breakdown for Glaxo SmithKline, Bristol-Myers Squibb and *Others (includes corresponding Graph/Chart)
• Viracept Dominates the Protease Inhibitors Market in the US
• Table 42: Protease Inhibitors Market by Brand Type in the US: 2005 Percentage Share Breakdown for Viracept, Crixivan, Norvir, Fortovase, Agenerase and Invirase (includes corresponding Graph/Chart)
• Table 43: Leading Players in the HIV Protease Inhibitors (PIs) Market in the US: 2005 Percentage Share Breakdown for Abbott Laboratories, Pfizer and *Others (includes corresponding Graph/Chart)
• Hepatitis B Infection Prevalence in the US
• Hepsera Dominates the Oral Hepatitis B Antivirals Market
• Table 44: Leading Brands in the Oral Hepatitis B Antivirals Market in the US: 2006 Percentage Share Breakdown for Hepsera, Epivir HBV and Baraclude (includes corresponding Graph/Chart)
• New Emerging Therapies for HBV Infection in the US
• Emerging Hepatitis B Infection Antivirals in Phase II Clinical Trials in the US
• Emerging Hepatitis B Infection Antivirals in Phase I Clinical Trials in the US
• Hepatitis C Antivirals Market in the US
• Table 45: Leading Players in the Hepatitis C Antivirals Market in the US: 2005 Percentage Share Breakdown for Schering Plough and *Others
• Table 46: Leading Brands in the Interferon Hepatitis C Antivirals Market in the US: 2006 Percentage Share Breakdown for Pegasys, PEG Intron, Copegus and Rebetol (includes corresponding Graph/Chart)
• HSV Antivirals in the US
• Table 47: Leading Players in the HSV Antivirals Market in the US: 2005 Percentage Share Breakdown for Glaxo SmithKline, Generics and *Others (includes corresponding Graph/Chart)
• Influenza Antivirals Market in the US
• Emerging Influenza Antivirals in the Clinical Development Stage in the US
• TIV Dominates the US Influenza Vaccines Market
• Table 48: Influenza Vaccines Market in the US: 2006 Percentage Share Breakdown by Vaccine Type for Treated (Killed) Influenza Vaccine (TIV) and Live Attenuated Influenza Vaccine (LAIV)
• Fluzone Rules the Roost in the Influenza Vaccines Market
• Table 49: Influenza Vaccines Market in the US: 2006 Percentage Share Breakdown by Vaccine Brand for Fluzone, Fluvirin, Fluarix and FluMist (includes corresponding Graph/Chart)
• Table 50: Leading Players in the Influenza Antivirals Market in the US: 2005 Percentage Share Breakdown for Roche and *Others
• HIV/AIDS Prevalence in the US
• Homosexual Males Emerges as a Significant Risk Group for HIV Infections in the US
• Table 51: Diagnosis of HIV/AIDS among Adult and Adolescent Males in the US: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug User (IDU), Homosexual Contact & IDU and Others (includes corresponding Graph/Chart)
• Table 52: Ethnic Group Distribution of HIV/AIDS Cases Among Men with Homosexual Contacts in the US: 2005 Percentage Share Breakdown for Whites, African Americans, Latin Americans, Asian/Pacific Islander and American Indian/Alaska Native (includes corresponding Graph/Chart)
• Women, a High Risk Group for HIV/AIDS in the US
• Table 53: AIDS Cases Reported in the US Among Females 13 and Older: 2005 Percentage Share Breakdown by Ethnic Community for African American Women, Latin American Women, White Women and Others (includes corresponding Graph/Chart)
• Table 54: Diagnosis of HIV/AIDS among Adult and Adolescent Females in the US: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug User (IDU) and Others (includes corresponding Graph/Chart)
• African Americans, the Leading High Risk Ethnic Group for HIV Infection in the US
• Table 55: Individuals Living with AIDS in the US: 2005 Percentage Share Breakdown by Ethnic Community for African Americans, Whites, Latin Americans and Others (includes corresponding Graph/Chart)
• Latinos, the Second Major Ethnic Risk Group for HIV Infection in the US
• Zidovudine (ZDV) Emerges as a Major Drug to Prevent Mother-to-Child Transmission of HIV Infection
• An Overview of Sexually Transmitted Diseases (STDs) in the US
• Regulatory Environment for HIV/AIDS in the US
• Product Launches
• Strategic Corporate Developments
• Focus on Key Players
• 3M
• Abbott Laboratories
• Amazon Biotech
• Bristol-Myers Squibb
• FermaVir Pharmaceuticals
• Gilead Sciences
• Hemispherx Biopharma
• MedImmune Inc.
• Merck & Co.
• Novartis Pharmaceuticals
• Novelos Therapeutics
• Panacos Pharmaceuticals
• Pfizer Inc.
• Pharmasset
• Schering-Plough Corporation
• B. Market Analytics
• Table 56: US Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 57: US Recent Past, Current & Future Analysis for HIV Antivirals by Product Segment - RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 58: US 10-Year Perspective for HIV Antivirals by Product Segment - Percentage Breakdown of Value Sales for RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for the Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
• Table 59: US Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 60: US 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis BAntivirals for the Years 2000, 2006 & 2010

2. Japan

• A. Market Analysis
• Japanese Antivirals Market Perspective
• HIV Infection Prevalence in Japan
• Hepatitis B & C Antivirals Dominate the Japanese Antivirals Market
• Japan, the Second Largest Market for Hepatitis C Infection in the World
• Table 61: Leading Drug Brands for Hepatitis C Antivirals in Japan: 2005, 2006 and 2008E Percentage Share Breakdown for PEG-Intron, Pegasys, Intron A, Advaferon, Sumiferon, Feron and Others (includes corresponding Graph/Chart)
• Product Launch
• Strategic Corporate Developments
• Focus on Key Players
• Daiichi Pharmaceutical Co.
• Japan Tobacco
• B. Market Analytics
• Table 62: Japanese Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 63: Japanese Recent Past, Current & Future Analysis for HIV Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 64: Japanese Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 65: Japanese 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010

3. Europe

• A. Market Analysis
• France - The Largest and the Fastest Growing Market for Antivirals
• HIV Therapy Dominates the Antivirals Market
• Table 66: Antivirals Market by Type in Europe: 2006 Percentage Share Breakdown for HIV Antivirals, Hepatitis B & C Antivirals, and Other Antivirals (includes corresponding Graph/Chart)
• HIV/AIDS Prevalence in Europe
• HIV/AIDS Statistics in Western Europe
• UK Dominates the Market for Western Europe for HIV Infection
• Table 67: Diagnosis of HIV Infection among Adults in Western Europe: 2005 Percentage Share Breakdown by Region for UK, Portugal, **France, Germany, The Netherlands, *Italy, Belgium, Switzerland and Others (includes corresponding Graph/Chart)
• HIV/AIDS Statistics in Central Europe
• Poland Dominates the Market for Central Europe for HIV Infection
• Table 68: Diagnosis of HIV Infection among Adults in Central Europe: 2005 Percentage Share Breakdown by Region for Poland, Romania, Turkey, Serbia & Montenegro, Czech Republic, Hungary, Bulgaria and Others (includes corresponding Graph/Chart)
• HIV/AIDS Statistics in Eastern Europe
• Russia Dominates the Market for Eastern Europe for HIV Infection
• Table 69: Diagnosis of HIV Infection among Adults in Eastern Europe: 2005 Percentage Share Breakdown by Region for Russia, *Ukraine, Uzbekistan, Belarus, Estonia, Kazakhstan, Republic of Moldova, Latvia and Others (includes corresponding Graph/Chart)
• Herpes Antivirals
• Strategic Corporate Developments
• B. Market Analytics
• Table 70: European Recent Past, Current & Future Analysis for Antivirals by Geographic Region - France, Germany, Italy, UK, Spain and Rest of Europe Markets Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 71: European 10-Year Perspective for Antivirals by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain and Rest of Europe for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
• Table 72: European Recent Past, Current & Future Analysis for HIV Antivirals by Product Segment - RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 73: European 10-Year Perspective for HIV Antivirals by Product Segment -Percentage Breakdown of Value Sales for RTIs (NRTIs and NNTRIs), PIs and Other HIV Antivirals for Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
• Table 74: European Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 75: European 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment- Percentage Breakdown of Value Sales for Hepatitic C Antivirals and Hepatitis B Antivirals for Years 2000, 2006 & 2010

3a. France

• A. Market Analysis
• France the Largest and Fastest Growing Antivirals Market in Europe
• Strategic Corporate Developments
• B. Market Analytics
• Table 76: French Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

3b. Germany

• A. Market Analysis
• Germany the Second Largest and Fastest Growing Antivirals Market in Europe
• Strategic Corporate Developments
• Focus on Key Player
• Boehringer Ingelheim
• B. Market Analytics
• Table 77: German Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

3c. Italy

• A. Market Analysis
• Strategic Corporate Developments
• B. Market Analytics
• Table 78: Italian Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

3d. The United Kingdom

• Market Analysis
• UK the Third Largest Market for Antivirals in Europe
• HIV/AIDS Prevalence in the UK
• Table 79: Diagnosis of HIV Infection among Individuals in the UK: 2005 Percentage Share Breakdown by Ethnic Community for Whites, Black- Africans, Black-Caribbeans and Others (includes corresponding Graph/Chart)
• Table 80: Diagnosis of AIDS among Adult Males in the UK: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Blood/Tissue Transfer or Blood Factor and Others (includes corresponding Graph/Chart)
• Table 81: Diagnosis of AIDS among Adult Females in the UK: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU), Mother-to-Child Transfer, Blood/Tissue Transfer or Blood Factor and Others (includes corresponding Graph/Chart)
• Table 82: Diagnosis of HIV Infection in People in the UK: 2005 Percentage Share Breakdown by Region for England, Scotland, Wales and North Ireland (includes corresponding Graph/Chart)
• Drug Resistant HIV Strains Rising in the UK
• Rise in Sexually Transmitted Diseases Pose Health Risks
• Strategic Corporate Developments
• Focus on Key Player
• GlaxoSmithKline PLC
• B. Market Analytics
• Table 83: UK Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

3e. Spain

• A. Market Analysis
• B. Market Analytics
• Table 84: Spanish Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• 3f. Rest of Europe
• A. Market Analysis
• Russia
• Acute Supply Shortage of AIDS drugs Risks the Life of Many People in Russia
• Strategic Corporate Developments
• Focus on Key Players
• Hoffmann-La Roche (Switzerland)
• Novartis AG (Switzerland)
• B. Market Analytics
• Table 85: Rest of Europe Recent Past, Current & Future Analysis for Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)

4. Rest of World

• A. Market Analysis
• Canada
• HIV/AIDS Prevalence in Canada
• Table 86: Diagnosis of HIV Infection among Adult Males in Canada: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Homosexual Contact & IDU, Infection through Blood/Blood Products and Others (includes corresponding Graph/Chart)
• Table 87: Diagnosis of HIV Infection among Adult Females in Canada: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU), Infection through Blood/Blood Products and Others (includes corresponding Graph/Chart)
• Table 88: Diagnosis of AIDS among Adult Males in Canada: 2005 Percentage Share Breakdown by Transmission Category for Homosexual Contact, Heterosexual Contact, Injecting Drug Use (IDU), Homosexual Contact & IDU and Others (includes corresponding Graph/Chart)
• Table 89: Diagnosis of AIDS among Adult Females in Canada: 2005 Percentage Share Breakdown by Transmission Category for Heterosexual Contact, Injecting Drug Use (IDU) and Others (includes corresponding Graph/Chart)
• Table 90: Individuals Living with AIDS in Canada: 2005 Percentage Share Breakdown by Ethnic Community for Whites, Aboriginals, Blacks, South Asian/West Asian/Arab, Asians and Others (includes corresponding Graph/Chart)
• Hepatitis C Infection Prevalence in Canada
• Asia-Pacific
• HIV/AIDS Prevalence in Asia
• HIV Infection Among Males Rising
• Australia
• HIV/AIDS Prevalence in Australia
• Table 91: Diagnosis of HIV Infections in Australia: 2005 Percentage Share Breakdown by Region for New South Wales, Victoria, Queensland, Western Australia, South Australia, Australian Capital Territory and Others (includes corresponding Graph/Chart)
• Hepatitis C Infection Prevalence in Australia
• Table 92: Sources of Hepatitis C Infection Transmission in Australia: 2005 Percentage Share Breakdown by Transmission Category for Injecting Drug Use (IDU), Blood Transfusion/Medical, Tattoos/Piercing, Sexual Contact and Others (includes corresponding Graph/Chart)
• Bangladesh
• HIV/AIDS Prevalence in Bangladesh
• Cambodia
• HIV/AIDS Prevalence in Cambodia
• China
• Antivirals Market in China
• China Presents a Major Market for Hepatitis B Therapies
• HIV/AIDS Prevalence in China
• Hong Kong
• HIV/AIDS Prevalence in Hong Kong
• India
• Hepatitis B Vaccines Market in India
• Table 93: Hepatitis B Vaccine Market in India: 2005 Percentage Share Breakdown by Player for Shantha Biotech, Glaxo SmithKline and Others (includes corresponding Graph/Chart)
• HIV/AIDS Prevalence in India
• Table 94: AIDS Cases Diagnosed in India: 2005 Percentage Share Breakdown by Gender for Males and Females
• Table 95: Diagnosis of HIV/AIDS Cases in India: 2005 Percentage Share Breakdown by Transmission Category for Sexual Contact, Mother-to-Child Transfer, Injecting Drug Use (IDU), Blood and Blood Products, and Others (includes corresponding Graph/Chart)
• Table 96: Diagnosis of AIDS Cases in India: 2005 Percentage Share Breakdown by Geographic Region for Tamil Nadu, Maharashtra, Andhra Pradesh, Karnataka, Manipur, West Bengal, Kerala, Madhya Pradesh, Uttar Pradesh, Rajasthan and Others (includes corresponding Graph/Chart)
• India Emerging as a Major Market for HIV-Infected People in the World
• Table 97: Diagnosis of HIV Infection in India: 2005 Percentage Share Breakdown by Sub-Population for General Population, STD Patients, Injecting Drug Users (IDUs), Children and Female Sex Workers (FSWs) (includes corresponding Graph/Chart)
• Organizations Active in Executing HIV/AIDS Control and Prevention Programs
• Table 98: Institutional Funding for HIV/AIDS Control Programs in India: 2005 Percentage Share Breakdown by Funding Organization for Public Bodies, Bilateral Organizations, World Bank, Multilateral Organizations and Global Funds (includes corresponding Graph/Chart)
• India Steps Up Infrastructure Development to Control
• and Prevent the Spread of Viral Infections
• New Treatment Options to Fight Against HIV Infection
• AIDS Control Programs for Rural Youths in India
• Indonesia
• HIV/AIDS Prevalence in Indonesia
• Myanmar (Burma)
• HIV/AIDS Prevalence in Myanmar
• Nepal
• HIV/AIDS Prevalence in Nepal
• New Zealand
• HIV/AIDS Prevalence in New Zealand
• Pakistan
• HIV/AIDS Prevalence in Pakistan
• Singapore
• HIV/AIDS Prevalence in Singapore
• South Korea
• HIV/AIDS Prevalence in South Korea
• Thailand
• HIV/AIDS Prevalence in Thailand
• Viet Nam
• HIV/AIDS Prevalence in Viet Nam
• Hepatitis B Infection Prevalence in Viet Nam
• Latin America
• HIV/AIDS Prevalence in Latin America
• Table 99: Diagnosis of People Living with HIV/AIDS in Latin America: 2005 Percentage Share Breakdown by Geographic Region for Brazil, Mexico, Colombia, Argentina, Venezuela, Peru, Honduras, Guatemala, El Salvador, Ecuador, Panama, Paraguay and Others (includes corresponding Graph/Chart)
• Table 100: Diagnosis of AIDS Related Deaths in Latin America: 2005 Percentage Share Breakdown by Geographic Region for Brazil, Colombia, Mexico, Venezuela, Peru, Argentina, Honduras, Guatemala, El Salvador, Ecuador, Panama and Others (includes corresponding Graph/Chart)
• HIV/AIDS Prevalence in the Caribbean Region
• Table 101: Diagnosis of People Living with HIV/AIDS in Caribbean: 2005 Percentage Share Breakdown by Geographic Region for Haiti, Dominican Republic, Trinidad and Tobago, Jamaica, Bahamas, Cuba and Barbados (includes corresponding Graph/Chart)
• Table 102: Diagnosis of AIDS Related Deaths in Caribbean: 2005 Percentage Share Breakdown by Geographic Region for Haiti, Dominican Republic, Trinidad and Tobago, Jamaica and Others (includes corresponding Graph/Chart)
• Africa
• HIV/AIDS Prevalence in Sub-Saharan Africa
• Table 103: Diagnosis of People Living with HIV/AIDS in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Nigeria, Mozambique, Zimbabwe, United Republic of Tanzania, Kenya, Ethiopia, Zambia, Democratic Republic of Congo, Uganda and Others (includes corresponding Graph/Chart)
• Table 104: Diagnosis of AIDS Related Deaths in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Nigeria, Zimbabwe, Mozambique, United Republic Of Tanzania, Kenya, Ethiopia, Zambia, Uganda, Malawi and Others (includes corresponding Graph/Chart)
• Table 105: Diagnosis of AIDS Related Orphans in Sub-Saharan Africa: 2005 Percentage Share Breakdown by Geographic Region for South Africa, Kenya, United Republic Of Tanzania, Zimbabwe, Uganda, Nigeria, Ethiopia, Zambia, Democratic Republic of Congo, Malawi and Others (includes corresponding Graph/Chart)
• South Africa
• Television Exposures Induces Healthy Lifestyle Changes Among People to Combat HIV/AIDS Epidemic
• HIV/AIDS Prevalence in South Africa
• Middle East
• HIV/AIDS Prevalence in Middle East
• Product Launches
• Strategic Corporate Developments
• Focus on Select Players
• Bukwang Pharm (South Korea)
• Benitec Limited (Australia)
• B. Market Analytics
• Table 106: Rest of World Recent Past, Current & Future Analysis for Antivirals Market Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 107: Rest of World Recent Past, Current & Future Analysis for Hepatitis B & C Antivirals by Product Segment - Hepatitis C Antivirals and Hepatitis B Antivirals Independently Analyzed by Annual Sales for the Years 2000 through 2010 in US$ Million (includes corresponding Graph/Chart)
• Table 108: Rest of World 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010 (includes corresponding Graph/Chart)
• Table 109: Rest of World 10-Year Perspective for Hepatitis B & C Antivirals by Product Segment - Percentage Breakdown of Value Sales for Hepatitis C Antivirals and Hepatitis B Antivirals for the Years 2000, 2006 & 2010

IV. COMPETITION

• 1. 3M Company (USA)
• Table 110: First Quarter Sales Analysis: 2005-2006 (In US$ billion)
• Table 111: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion)
• Table 112: Annual Sales Analysis: 2004-2005 (In US$ billion)
• Table 113: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
• Table 114: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
• 3M Pharmaceuticals (USA)
• 2. Abbott Laboratories (USA)
• Table 115: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 116: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 117: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
• Table 118: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 119: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 120: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 121: Annual sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 3. Achillion Pharmaceuticals, Inc. (USA)
• 4. Adithya Pharmaceuticals Pvt., Ltd. (India)
• 5. Adventrx Pharmaceuticals, Inc. (USA)
• 6. Aeterna Zentaris, Inc. (Canada)
• Table 122: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 123: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 124: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 125: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 7. Aethlon Medical, Inc. (USA)
• 8. Alfacell Corporation (USA)
• 9. Alnylam Pharmaceuticals, Inc. (USA)
• Table 126: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 127: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 128: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 10. Amarillo Biosciences (USA)
• Table 129: Half Yearly Sales Analysis 2005-2006 (H1) (US$ Million)
• Table 130: Annual Sales Analysis 2004-2005 (US$ Million)
• 11. Amazon Biotech (USA)
• 12. Amgen, Inc. (USA)
• Table 131: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 132: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 133: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 13. Anadys Pharmaceuticals (USA)
• Table 134: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 135: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 136: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 14. Antigenics, Inc. (USA)
• Table 137: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 138: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 139: Annual Sales Analysis: 2004-2005 (In US$ million)
• 15. Ares Serono (France)
• 16. Array BioPharma, Inc. (USA)
• Table 140: Annual Sales Analysis: 2004-2005 (In US$ million)
• 17. Arrow Pharmaceuticals (Australia)
• 18. Aspen Pharmacare Holding Ltd. (South Africa)
• Table 141: Annual Sales Analysis: 2004-2005 (In R million)
• 19. Astral Pharmaceuticals (India)
• 20. Astellas Pharma, Inc. (Japan)
• 21. AstraZeneca PLC (UK)
• Table 142: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 143: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million)
• Table 144: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 145: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 22. Aurobindo Pharma Ltd. (India)
• Table 146: Annual Sales Analysis: 2004-2005 (In INR million)
• 23. Avanir Pharmaceuticals (USA)
• Table 147: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, June) (In US$ million)
• Table 148: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, June) (In US$ million)
• Table 149: Nine Months Sales Analysis by Segment: 2005-2006 (Nine Months ended, June) (In US$ million)
• Table 150: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 151: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 152: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• 24. Bavarian Nordic A/S (Denmark)
• Table 153: Half Yearly Sales Analysis: 2006-2005 (H1) (In DKK million)
• Table 154: Annual Sales Analysis: 2004-2005 (In DKK million)
• 25. Bayer HealthCare AG (Germany)
• Table 155: Annual Sales Analysis: 2004-2005 (In € million)
• Table 156: Annual Sales Analysis by Segment: 2004-2005 (In € million)
• Table 157: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)
• 26. Becton Dickinson and Company (USA)
• Table 158: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 159: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 160: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
• Table 161: Annual Sales Analysis: 2004-2005 (In US$ million)
• 27. Benitec Ltd. (Australia)
• 28. Biomerieux SA (France)
• 29. Biomira, Inc. (Canada)
• 30. Biota Holdings Limited (Australia)
• Table 162: Annual Sales Analysis: 2005-2006 (In US$ million)
• 31. Biovail Pharmaceuticals (Canada)
• 32. Boehringer Ingelheim GmbH (Germany)
• Roxane Laboratories, Inc. (USA)
• 33. Bristol-Myers Squibb Company (USA)
• Table 163: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
• Table 164: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ billion)
• Table 165: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion)
• Table 166: Annual Sales Analysis: 2004-2005 (In US$ billion)
• Table 167: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion)
• Table 168: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
• Table 169: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
• 34. Bukwang Pharmaceutical Company Limited (South Korea)
• 35. Cavidi Tech AB (Sweden)
• 36. Celldex Therapeutics, Inc. (USA)
• 37. CEL-SCI Corporation (USA)
• Table 170: Nine Months Sales Analysis: 2005-2006 (Nine Months Ended, June) (In US$ thousand)
• Table 171: Nine Months Sales Analysis by Quarter: 2005-2006 (Nine Months Ended, June) (In US$ thousand)
• Table 172: Annual Sales Analysis: 2004-2005 (In US$ thousand)
• 38. ChemBridge Research Laboratories, Inc. (USA)
• 39. Chimerix, Inc. (USA)
• 40. Chongqing Jiachen Product Manufacturing Co., Ltd. (China)
• 41. Coley Pharmaceutical Group, Inc. (USA)
• Table 173: Half-Yearly Sales Analysis: 2006-2005 (H1) (In Can$ thousand)
• Table 174: Annual Sales Analysis: 2004-2005 (In Can$ thousand)
• Table 175: Annual Sales Analysis by Quarter: 2005-2004 (In Can$ thousands)
• 42. Cornerstone BioPharma, Inc. (USA)
• 43. Cubist Pharmaceuticals, Inc. (USA)
• Table 176: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 177: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 178: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
• Table 179: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 180: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 44. Cytogenix, Inc. (USA)
• 45. Daiichi Pharmaceutical Co., Ltd. (Japan)
• Table 181: Annual Sales Analysis: 2004-2005 (In ¥ billion)
• Table 182: Annual Sales Analysis by Segment: 2004-2005 (In ¥ billion)
• 46. Dainippon Sumitomo Pharma Company Ltd. (Japan)
• Table 183: Annual Sales Analysis: 2005-2006 (In ¥ million)
• 47. Digene Corporation (USA)
• Table 184: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 185: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 48. E. I. Du Pont De Nemours and Company (USA)
• Table 186: Annual Sales Analysis: 2004-2005 (In US$ billion)
• Table 187: Annual Sales Analysis by Quarter: 2004-2005 (In US$ billion)
• Table 188: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
• Table 189: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
• 49. Eli Lilly and Company (USA)
• Table 190: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ million)
• Table 191: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ million)
• Table 192: Half Yearly Sales Analysis by Product: 2004-2005 (H1) (In US$ million)
• Lilly Research Labs (USA)
• 50. Enanta Pharmaceuticals, Inc. (USA)
• 51. Endo Labs (USA)
• 52. Enzo Diagnostics, Inc. (USA)
• 53. F. Hoffmann-La Roche Ltd. (Switzerland)
• Table 193: First Quarter Sales Analysis: 2005-2006 (In CHF billion)
• Table 194: First Quarter Sales Analysis by Segment: 2005-2006 (In CHF billion)
• Table 195: Annual Sales Analysis: 2004-2005 (In CHF billion)
• Roche Laboratories, Inc. (USA)
• 54. FermaVir Pharmaceuticals, Inc. (USA)
• 55. Flamel Technologies SA (France)
• Table 196: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 197: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 198: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 199: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 56. Forest Laboratories, Inc. (USA)
• Table 200: First Quarter Sales Analysis: 2006-2007 (In US$ billion)
• Table 201: Annual Sales Analysis: 2004-2006 (In US$ billion)
• Table 202: Annual Sales Analysis by Quarter: 2005-2006 (In US$ billion)
• Table 203: Annual Sales Analysis by Product: 2005-2006 (In US$ billion)
• Table 204: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ billion)
• 57. Galapagos NV (Belgium)
• 58. Genentech, Inc. (USA)
• Table 205: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 206: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 207: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 59. Gen-Probe, Inc. (USA)
• Table 208: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 209: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 210: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• 60. Gilead Sciences, Inc. (USA)
• Table 211: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In USS$ million)
• Table 212: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In USS$ million)
• Table 213: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 214: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 61. Girindus AG (Germany)
• 62. GlaxoSmithKline PLC (UK)
• Table 215: Annual Sales Analysis: 2003-2005 (In £ million)
• Table 216: Annual Sales Analysis by Segment: 2004-2005 (In £ million)
• Table 217: Annual Sales Analysis by Segment: 2003-2004 (In £ million)
• 63. Health Enhancement Products, Inc. (USA)
• 64. Hemispherx Biopharma, Inc. (USA)
• Table 218: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousand)
• 65. Hetero Drugs Ltd. (India)
• 66. Human Genome Sciences, Inc. (USA)
• Table 219: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)
• Table 220: Annual Sales Analysis: 2003-2005 (In US$ million)
• 67. Idenix Pharmaceuticals, Inc. (USA)
• Table 221: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 222: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 223: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 68. Idera Pharmaceuticals, Inc. (USA)
• 69. Indian Immunologicals Ltd. (India)
• 70. Innogenetics NV (Belgium)
• Table 224: Half Yearly Sales Analysis: 2004-2005 (H1) (In € million)
• Table 225: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In € million)
• 71. Inovio Biomedical Corporation (USA)
• Table 226: Half Yearly Sales Analysis by: 2005-2006 (H1) (In US$ million)
• Table 227: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 228: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 229: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 72. Intarcia Therapeutics Inc. (USA)
• 73. Intercell AG (Austria)
• Table 230: Half Yearly Sales Analysis: 2005-2006 (H1) (In € thousand)
• Table 231: Annual Sales Analysis: 2004-2005 (In € thousand)
• 74. InterMune, Inc. (USA)
• Table 232: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 233: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
• Table 234: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million)
• Table 235: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 236: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 237: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 75. Isis Pharmaceuticals, Inc. (USA)
• Table 238: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 239: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ million)
• Table 240: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 241: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 242: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• 76. Japan Tobacco, Inc. (Japan)
• Table 243: Annual Sales Analysis: 2004-2006 (In ¥ billion)
• Table 244: Annual Sales Analysis by Segment: 2005-2006 (In ¥ billion)
• Table 245: Annual Sales Analysis by Geographic Region: 2005-2006 (In ¥ billion)
• Table 246: Annual Sales Analysis by Segment: 2004-2005 (In ¥ billion)
• Table 247: Annual Sales Analysis by Geographic Region: 2004-2005 (In ¥ billion)
• 77. Johnson & Johnson (USA)
• Table 248: First Quarter Sales Analysis: 2005-2006 (In US$ billion)
• Table 249: First Quarter Sales Analysis by Segment: 2005-2006 (In US$ billion)
• Table 250: First Quarter Sales Analysis by Geographic Region: 2005-2006 (Q1) (In US$ billion)
• Janssen LP (USA)
• Ortho-Clinical Diagnostics (USA)
• Ortho Biotech Products - Tibotec Therapeutics Division (USA)
• Tibotec Pharmaceuticals Ltd. (Ireland)
• 78. Koronis Pharmaceuticals, Inc. (USA)
• 79. Lupin Limited (India)
• Table 251: First Quarter Sales Analysis: 2006-2007 (In INR billion)
• Table 252: Annual Sales Analysis: 2004-2006 (In INR billion)
• 80. Medigene AG (Germany)
• Table 253: Half Yearly Sales Analysis: 2005-2006 (H1) (In ¥ million)
• Table 254: Half Yearly Sales Analysis by Quarter: 2005-2006 (In ¥ million)
• Table 255: Annual Sales Analysis: 2004-2005 (In ¥ million)
• 81. Medimmune, Inc. (USA)
• Table 256: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 257: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 258: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 259: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 82. Medivir AB (Sweden)
• Table 260: Annual Sales Analysis: 2004-2005 (In SEK million)
• 83. Merck & Company, Inc. (USA)
• Table 261: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 262: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 263: Half Yearly Sales Analysis by Product: 2005-2006 (H1) (In US$ million)
• Table 264: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 265: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 266: Annual Sales Analysis by Product: 2004-2005 (In US$ million)
• Table 267: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• Merck Research Laboratories (USA)
• 84. MGI Pharma, Inc. (USA)
• Table 268: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 269: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 270: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 85. Migenix, Inc. (Canada)
• Table 271: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 272: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 86. Monogram Biosciences, Inc. (USA)
• Table 273: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 274: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 275: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 87. Novactyl, Inc. (USA)
• 88. Novartis AG (Switzerland)
• Table 276: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 277: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ million)
• Table 278: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 279: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 280: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• Chiron Corporation (USA)
• Novartis Pharmaceuticals Corporation (USA)
• Sandoz International GmbH (Germany)
• 89. Novelos Therapeutics (USA)
• Table 281: Annual Sales Analysis: 2004-2005 (In US$ million)
• 90. Novosom AG (Germany)
• 91. Nucleonics, Inc. (USA)
• 92. Oncogene Science, Inc. (USA)
• 93. OraSure Technologies, Inc. (USA)
• Table 282: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 283: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 284: Half Yearly Sales Analysis by Segment: 2005-2006 (In US$ million)
• Table 285: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ million)
• Table 286: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 287: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 288: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• Table 289: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 94. Oxford BioMedica PLC (UK)
• Table 290: Annual Sales Analysis: 2004-2005 (In £ million)
• 95. Panacos Pharmaceuticals, Inc. (USA)
• 96. Pasteur Merieux Connaught (France)
• 97. PDL BioPharma, Inc. (USA)
• Table 291: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 292: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 293: Annual Sales Analysis: 2003-2005 (In US$ million)
• 98. Peregrine Pharmaceuticals, Inc. (USA)
• Table 294: Annual Sales Analysis: 2004-2006 (In US$ million)
• Table 295: Annual Sales Analysis by Quarter: 2005-2006 (In US$ million)
• Table 296: Annual Sales Analysis by Segment: 2005-2006 (In US$ million)
• Table 297: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)
• 99. Pfizer, Inc. (USA)
• Table 298: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
• Table 299: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ billion)
• Table 300: Half Yearly Sales Analysis by Geographic Region: 2005-2006 (H1) (In US$ billion)
• Table 301: Annual Sales Analysis: 2004-2005 (In US$ billion)
• 100. Pharmasset, Inc. (USA)
• 101. Pharmexa A/S (Denmark)
• Table 302: Half Yearly Sales Analysis: 2005-2006 (H1) (In DKK million)
• 102. Procter & Gamble Pharmaceuticals (USA)
• 103. Receptopharm, Inc. (USA)
• 104. REPLICor, Inc. (Canada)
• 105. Rhein Biotech NV (The Netherlands)
• 106. Sanofi-Aventis (France)
• Table 303: Half Yearly Sales Analysis: 2005-2006 (H1) (In € million)
• Table 304: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In € million)
• Table 305: Annual Sales Analysis: 2004-2005 (In € million)
• Table 306: Annual Sales Analysis by Segment: 2004-2005 (In € million)
• Table 307: Annual Sales Analysis by Geographic Region: 2004-2005 (In € million)
• 107. Sareum Ltd. (UK)
• 108. Schering AG (Germany)
• Table 308: First Quarter Sales Analysis: 2005-2006 (In € billion)
• Table 309: First Quarter Sales Analysis by Segment: 2005-2006 (In € billion)
• Table 310: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In € billion)
• Table 311: Annual Sales Analysis: 2004-2005 (In € billion)
• Table 312: Annual Sales Analysis by Segment: 2004-2005 (In € billion)
• Table 313: Annual Sales Analysis by Geographic Region: 2004-2005 (In € billion)
• Schering-Plough Corporation (USA)
• 109. SciClone Pharmaceuticals, Inc. (USA)
• Table 314: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 315: Annual Sales Analysis: 2004-2005 (In US$ million)
• 110. Scigen Ltd. (Australia)
• Table 316: Annual Sales Analysis: 2005-2006 (In S$ thousand)
• Table 317: Annual Sales Analysis by Geographic Region: 2005-2006 (In S$ thousand)
• 111. Serum Institute of India Ltd. (India)
• 112. SGX Pharmaceuticals, Inc.(USA)
• Table 318: First Quarterly Sales Analysis: 2005-2006 (In US$ million)
• Table 319: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• Table 320: Annual Sales Analysis: 2004-2005 (In US$ million)
• 113. Shantha Biotechnics Pvt., Ltd. (India)
• 114. Shionogi & Co., Ltd. (Japan)
• Table 321: Annual Sales Analysis: 2004-2005 (In ¥ million)
• Table 322: Annual Sales Analysis by Segment: 2004-2005 (In ¥ million)
• 115. Sunesis Pharmaceuticals, Inc. (USA)
• Table 323: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 324: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 325: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 326: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 116. Takeda Pharmaceutical Company Limited (Japan)
• Table 327: Annual Sales Analysis: 2004-2006 (In ¥ billion)
• 117. Targeted Genetics Corporation (USA)
• Table 328: Half Yearly Sales Analysis: 2005-2006 (In US$ million)
• Table 329: Annual Sales Analysis: 2003-2005 (In US$ million)
• 118. TEVA Pharmaceutical Industries Ltd. (Israel)
• Table 330: Half Yearly Sales Analysis: 2004-2005 (H1) (In US$ billion)
• Table 331: Half Yearly Sales Analysis by Segment: 2004-2005 (H1) (In US$ billion)
• Table 332: Half Yearly Geographic Sales Analysis: 2004-2005 (H1) (In US$ billion)
• Ivax Corporation (USA)
• 119. The Immune Response Corporation (USA)
• Table 333: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ thousand)
• Table 334: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ thousand)
• Table 335: Half Yearly Sales Analysis by Segment: 2005-2006 (H1) (In US$ thousand)
• Table 336: Annual Sales Analysis: 2003-2005 (In US$ thousand)
• Table 337: Annual Sales Analysis by Quarter: 2004-2005 (In US$ thousand)
• Table 338: Annual Sales Analysis by Segment: 2004-2005 (In US$ thousand)
• 120. Three Rivers Pharmaceuticals (USA)
• 121. Titan Pharmaceuticals, Inc. (USA)
• 122. Trimeris, Inc. (USA)
• Table 339: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• 123. Trinity Biotech PLC (Ireland)
• Table 340: First Quarter Sales Analysis: 2005-2006 (In US$ million)
• Table 341: First Quarter Sales Analysis by Product: 2005-2006 (In US$ million)
• Table 342: First Quarter Sales Analysis by Geographic Region: 2005-2006 (In US$ million)
• Table 343: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 344: Annual Sales Analysis by Product: 2004-2005 (In US$ million)
• Table 345: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 124. Tripep AB (Sweden)
• 125. Valeant Pharmaceuticals International (USA)
• Table 346: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 347: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 348: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 349: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 126. VaxGen, Inc. (USA)
• 127. Vertex Pharmaceuticals, Inc. (USA)
• Table 350: First Quarter Sales Analysis: 2006-2005 (In US$ million)
• Table 351: Annual Sales Analysis: 2003-2005 (In US$ million)
• Table 352: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 128. Vical, Inc. (USA)
• Table 353: Half Yearly Sales Analysis: 2005-2006 (In US$ million)
• Table 354: Half Yearly Sales Analysis by Quarter: 2005-2006 (In US$ million)
• Table 355: Annual Sales Analysis: 2004-2005 (In US$ million)
• Table 356: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)
• 129. Vion Pharmaceuticals (USA)
• 130. Viragen, Inc. (USA)
• Table 357: Annual Sales Analysis: 2004-2006 (In US$ million)
• Table 358: Annual Sales Analysis by Geographic Region: 2005-2006 (In US$ million)
• Table 359: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)
• 131. Virco Laboratories, Inc. (USA)
• 132. ViroPharma, Inc. (USA)
• Table 360: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 361: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 362: Annual Sales Analysis: 2004-2005 (In US$ million)
• 133. Viscount Pharma, Inc. (Canada)
• 134. Vybion, Inc. (USA)
• 135. Wyeth (USA)
• Table 363: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ billion)
• Table 364: Half Yearly Sales Analysis by Segment: 2006-2005 (H1) (In US$ billion)
• Table 365: Annual Sales Analysis: 2004-2005 (In US$ billion)
• Table 366: Annual Sales Analysis by Segment: 2004-2005 (In US$ billion)
• Table 367: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ billion)
• 136. Xenomics, Inc. (USA)
• 137. XTL Biopharmaceuticals Ltd. (USA)
• Table 368: Annual Sales Analysis: 2004-2005 (In US$ million)
• 138. ZymeTx, Inc. (USA)
• 139. ZymoGenetics, Inc. (USA)
• Table 369: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)
• Table 370: Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)
• Table 371: Annual Sales Analysis: 2004-2005 (In US$ million)